
Real-world Impact of Treated Hereditary Angioedema Attacks on Patients' Employment and Work Productivity

Timothy Craig¹, Paula Busse², Sandra Christiansen³, <u>Maeve O'Connor⁴</u>, Cristine Radojicic⁵, Julie Ulloa⁶, Sherry Danese⁶, Tomas Andriotti⁷, Paul Audhya⁷, Vibha Desai⁷

¹The Pennsylvania State University School of Medicine, State College, PA, USA; ⁴Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, USA; ⁵Duke University School of Medicine, Durham, NC, USA; ⁶Outcomes Insights, Agoura Hills, CA, USA; ⁷KalVista Pharmaceuticals, Cambridge, MA, USA



1. Betschel S, Badiou J, Binkley K, et al. Allergy, Asthma & Clinical *Immunology*. 2019;15(1):72. doi:10.1186/s13223-019-0376-8

- 2. Busse PJ, Christiansen SC, Riedl MA, et al. Allergy Clin Immunol *Pract.* 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046
- 3. Maurer M, Magerl M, Betschel S, et al. *Allergy.* 2022;77(7):1961-1990. doi:10.1111/all.15214

Table 1. US Participant Demographics						
	Total (n=94)	Employed (n=42)				
Current Mean Age, Years (SD)	39.4 (17.4)	39 (12.5)				
Mean Age at Diagnosis, Years (SD)	18 (12.6)	20.2 (13)				
НАЕ Туре						
Type 1	81%	86%				
Type 2	19%	14%				
Gender						
Female	72%	73%				
Race / Ethnicity						
White	87%	83%				
Hispanic or Latino	9%	10%				
Black / African American	3%	2%				
American Indian/Alaskan Native	2%	5%				
Asian	3%	2%				
Other	1%					
Payer Coverage						
Private or commercial health insurance	69%	86%				
Medicare	16%	5%				
Medicaid	14%	2%				
Other	8%	10%				

Figure 1. On-Demand Therapy Used for Last Treated Attack					
On-Demand Therapy ^a		On-demand Treatment Only (n=24) ^a	On-demand Treatment + LTP (n=18) ^a		
Icatibant 7	′1%	71%	72%		
Recombinant C1 Esterase Inhibitor		21%	17%		
Plasma Derived C1 Esterase Inhibitor 7%		4%	11%		
Ecallantide 2%		4%	0%		

Acknowledgments

The authors wish to thank Jason Allaire, PhD, of Generativity Health Outcomes Research for his assistance with this poster. Funding for Dr. Allaire was provided by KalVista Pharmaceuticals.

•	10% of emp
	≥ 8 hou
	5 to < 8 hou
	2 to < 5 hou
	1 to < 2 hou
	< 1 hc
	Figure 3. Ti

Mild
Moderate
Severe

Very Severe 0% ^aSurvey question: How severe was the attack when you decided to treat it? ^b% of Employed Participants. demand; 67% LTP)

In	itial Site of Attack ^a	On-demand Treatment Only (n=24) ^a	On-demand Treatment + LTP (n=18) ^a
Abdominal/Stomach	64%	67%	61%
Peripheral	14%	13%	17%
Face	7%	13%	0%
Throat	7%	8%	6%
Genitals	5%	0%	11%
Trunk	2%	1%	1%
^a % of Employed Participants			
			Conc

- I reatment was frequently delayed and often attacks were moderate or severe at the time of treatment • Despite treatment, HAE attacks were associated with activity impairment and impact on work lives of employed participants resulting in substantial:

25%

71%

4%

0%

62%

33%


50%


17%

0%

- Absenteeism
- Reduced productivity
- Presenteeism

Results me to Treatment 19% 14% 45% 17% ours 5% % of Employed Participants 19% of employed participants treated their HAE attack in <1 hour Figure 4. Patient-reported Attack Severity at the Time of Treatment^a **On-demand** On-demand Treatment Treatment Attack Severity^b + LTP Only (n=24)^b (n=18)^b





Impairments in their ability to work

• The impact was substantial for both patients taking on-demand treatment only and those taking on-demand plus LTP Compliance with HAE treatment guidelines may reduce the negative impact of attacks on the work lives of employed participants

Presented Eastern Allergy Conference 2024. May 30 – June 2, in Palm Beach, FL

To view this poster after the presentation, visit KalVista Virtual Medical Booth

• Thirty participants (72%) rated their attack severity as moderate to severe (75% On-

29%

10%





